DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/008994.6 A1 Olalde Rangel (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/008994.6 A1 Olalde Rangel (43) Pub US 2008.00899.46A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/008994.6 A1 Olalde Rangel (43) Pub. Date: Apr. 17, 2008 (54) SYNERGISTIC PHYTOCEUTICAL A6IR 36/21 (2006.01) COMPOSITIONS A6IR 36/232 (2006.01) A6IR 36/258 (2006.01) (76) Inventor: Jose Angel Olalde Rangel, Caracas A6IR 36/28 (2006.01) (VE) A6IR 36/286 (2006.01) A6IR 36/3 (2006.01) Correspondence Address: A6IR 36/4I (2006.01) BAKER & MCKENZE LLP A6IR 36/45 (2006.01) Pennzoil Place, South Tower A6IR 36/48 (2006.01) 711 Louisiana, Suite 3400 A6IR 36/7 (2006.01) HOUSTON, TX 77002-2716 (US) A6IP 7/00 (2006.01) A6IP 5/00 (2006.01) (21) Appl. No.: 11/924,122 A6IP 9/00 (2006.01) (52) U.S. Cl. .................... 424/548; 424/195.15; 424/725: (22) Filed: Oct. 25, 2007 424/726; 424/728; 424/732: 424/737; 424/752; 424/755; Related U.S. Application Data 424/757; 424/773; 424/775 (62) Division of application No. 1 1/271,940, filed on Nov. (57) ABSTRACT 10, 2005, now Pat. No. 7,303,772. Phytoceutical compositions for the prevention and treatment Publication Classification of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of (51) Int. Cl. plants is taught, as well as principles for varying the for A6 IK 36/00 (2006.01) mulations based on categorizing plants into one of three A6 IK 35/32 (2006.01) groups, Energy, Bio-Intelligence, and Organization and A6 IK 36/074 (2006.01) selecting several plants from each group. Such combinations A6 IK 36/16 (2006.01) have synergistic effects, with minimal side effects. Patent Application Publication Apr. 17, 2008 Sheet 1 of 3 US 2008/008994.6 A1 Figars f: Fatigraphie sewidiaries of iaitetic Fest rismissics, irreiading isfigth of treatnessert sefree phasis. ? Doppier titrestand fe Patent Application Publication Apr. 17, 2008 Sheet 2 of 3 US 2008/008994.6 A1 figure 2: Pts -before w after eitasaragrapefic carparison. Afterwal fetween echesonagranrass if trantis SSSSSS SS 87. Patent Application Publication Apr. 17, 2008 Sheet 3 of 3 US 2008/008994.6 A1 Figure 3: Photographic eviderace of severe Psoriasis remissions, including length of treatner between photos US 2008/008994.6 A1 Apr. 17, 2008 SYNERGISTIC PHYTOCEUTICAL Polycystic Ovary Syndrome, ovarian cysts, fibrocystic COMPOSITIONS breast condition, uterine fibroids, dysfunctional uterine hem orrhage, female infertility, premenstrual syndrome, amenor PRIOR RELATED APPLICATIONS rhea, and the like. 0001. Not applicable. 0009. Another embodiment of the invention provides a composition for chronic skin disorders. It can be used alone FEDERALLY SPONSORED RESEARCH or combined with pharmaceuticals, and can be used to treat STATEMENT diseases such as psoriasis, dermatitis, skin infections, 0002) Not applicable. shingles (herpes Zoster), boils, eczema, rash, acne or burn, and the like. REFERENCE TO MICROFICHEAPPENDIX 0003) Not applicable. DETAILED DESCRIPTION OF THE FIGURES 0010 FIG. 1 shows representative examples of diabetic FIELD OF THE INVENTION foot lesions treated with the herbaria of Table 1. 0004 The invention relates to phytoceutical formulations 0011 FIG. 2 shows representative examples of PCOS used to treat a variety of diseases. The formulations are treated with the herbaria of Table 2. particular combinations of plants and have synergistic effect in combination. Principles for selecting beneficial formula 0012 FIG. 3 shows representative examples of psoriasis tions are provided. treated with the herbaria of Table 3. BACKGROUND OF THE INVENTION DETAILED DESCRIPTION OF THE 0005 The academic study of medicinal plants for the INVENTION treatment of diverse diseases has been nearly as pervasive as 0013 “Pharmaceutically acceptable excipients’ is used the study of Western medicines—The active principles from herein according to art accepted meanings, and includes many traditional medicines have been extracted from plants, those ingredients needed to formulate a medicine for mam the curative agents identified and their mechanisms of action malian use, including the use of gelatin capsules. determined. Plant based medicines are typically well toler ated, with less severe side effects as well as a Smaller range 0014 “Synergistic' or “synergy” is used herein to mean of side effects. However, despite the excellent medicinal that the effect is more than its additive property. In preferred qualities of many plants, they are individually insufficient to embodiments, the synergy is at least 1.5, 2, 5, or 10 fold. take chronic degenerative diseases into remission. In con 0015. By use of “plants,” what is meant herein is that the trast, while synthetic drugs can be highly effective, their use plant (or that portion with medicinal activity) is used whole, is often hampered by severe side effects. What is needed in ground, or as an extract. Also included are purified active the art are better treatment regimes with improved patient ingredients and derivatives thereof. However, it is believed tolerance, while providing Sufficient efficacy. that the best efficacy of plants used herein is achieved with the use of the entire plant or its extracts, rather than with the SUMMARY OF THE INVENTION use of isolated active ingredients. 0006. A number of known beneficial plants were classi fied according to their capacity to enhance the three main 0016 Further, although plants are named here according elements that support overall health: Energy (E), Bio-intel to commonly used nomenclature, with improving taxonomy ligence (I) and Organization (O). A synergistic effect is plants are often reclassified. Whenever a plant is referenced, expected when all three categories of herbs (E. I. O) are it includes related species with similar active ingredients. included in a formulation, preferably at least two or three or 0017. The following examples are illustrative only and four plants from each category. Thus, one embodiment of the should not serve to unduly limit the invention. invention provides a method of selecting additional disease treating formulations according to these principles. Three EXAMPLE 1. examples of formulations prepared in this way are provided and additional formulations are being prepared and tested. Plant Characteristics Circulatory Disorders 0007 Another embodiment of the invention provides an 0018 Angelica sinensis (Dong Quai or Angelica, also effective, natural composition for treating circulatory dis Angelica Archangelia, Angelica Pubescens and Angelica eases. The composition can be used alone, or can be com Sylvestris) contains terpenes (terpenes, mainly B-phelland bined with simultaneous use of one or more pharmaceutical rene, with B-bisabolene, B-caryophyllene, B-phellandrene, compositions. It can be used for the treatment of diabetic C- and B-pinene, limonene, linalool, borneol, acetaldehyde, lesions, obliterative arteriosclerosis, Leriche Syndrome menthadienes, and nitromenthadienes), macrocyclic lac (aorto-iliac obliteration), Buerger's disease (thromboangiitis tones (including tridecanolide, 12-methyl tridecanolide, obliterans), thrombophlebitis, chronic venous insufficiency, pentadecanolide), phthalates (such as hexamethylphthalate), Varicose veins, varicose ulcers, hemorrhoids, and the like. coumarins (especially flirocoumarin glycosides Such as 0008 Another embodiment of the invention provides a marmesin and apterin), angelicin and byakangelicin deriva composition for the treatment of feminine endocrine dis tives (osthol, umbelliferone, psoralen, bergapten, impera eases that can be used alone or combined with pharmaceu toren, XanthotoXol, Xanthotoxin, oxypeucedanin and more), ticals. It provides an effective medicine for diseases such as as well as various Sugars, plant acids, flavonoids, and sterols. US 2008/008994.6 A1 Apr. 17, 2008 0.019 Acanthopanax senticosus (Russian Ginseng, Sibe of c(GMP and cAMP levels and prolongation of the time rian Ginseng, Eleuthero, Devil's Shrub, Touch-me-not, Wild interval between the conversion of fibrinogen to fibrin. Pepper, Shigoka, Acantopanacis senticosus) contains terpe Ginsenosides have also been shown to be relatively potent noids (oleanolic acid), glycosides (Eleutheroside A (daucos platelet activating factor antagonists. It has antioxidant, terin), B1, C-G, I, K, L, M), phytosterols (B-sitosterol), anti-inflammatory, and hypolipidemic effects. The incorpo coumarins (Eleutheroside B1 and B3, isofraxidine), polysac ration of this phytomedicine into a composition provides at charides (eleutherans), volatile oils, caffeic acid, coniferyl least 206 active principles in a single therapeutic. aldehyde, and sugars. Eleuthero has been shown to bind to estrogen, progestin, and mineralocorticoid receptors, and 0023 Pfaffia paniculata (Suma, Brazilian Ginseng, Pfaf stimulate T-lymphocyte and natural killer cell production. It fia, Para Toda, Corango-acu; also Hebanthe paniculata, has activity anti-platelet aggregation activity similar to aspi Gomphrena paniculata, G. eriantha, Iresine erianthos, I. rin, as well as antioxidant activity. Russian Ginseng contains paniculata, I. tenuis, P. eriantha, Xeraea paniculata) con at least 40 active ingredients. tains active glycosides (beta-ecdysone and three ecdys teroids), pfaffic acids, phytosterols (sitosterol and estimas 0020 Rhaponticum carthamoides (Leuzea, or Maral terol). It also contains Saponins. Its germanium content Root) contains a mixture of compounds called, “levseins.” probably accounts for its properties as an oxygenator at the Levseins represents a complex of more than 10 ecdysterones cellular level,
Load more

Recommended publications
  • Taste Modulator and Method of Use Thereof Geschmacksmodulator Und Verfahren Zur Verwendung Davon Modulateur De Goût Et Son Procédé D’Utilisation
    (19) TZZ¥ZZ_T (11) EP 3 005 884 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A23L 27/10 (2016.01) A23L 7/126 (2016.01) 19.04.2017 Bulletin 2017/16 A21D 2/26 (2006.01) A21D 2/36 (2006.01) A23L 2/56 (2006.01) A61Q 11/00 (2006.01) (2017.01) (2006.01) (21) Application number: 15189164.5 A61K 8/97 A61K 36/232 A23L 23/00 (2016.01) (22) Date of filing: 09.10.2015 (54) TASTE MODULATOR AND METHOD OF USE THEREOF GESCHMACKSMODULATOR UND VERFAHREN ZUR VERWENDUNG DAVON MODULATEUR DE GOÛT ET SON PROCÉDÉ D’UTILISATION (84) Designated Contracting States: • JOHN, Thumpalasseril V. AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Morganville, NJ 07751 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • KIM, Jung-A PL PT RO RS SE SI SK SM TR Edgewater, NJ 07020 (US) • SINGH, Ajay Pratap (30) Priority: 10.10.2014 US 201414511963 Highland Park, NJ 08904 (US) (43) Date of publication of application: (74) Representative: Lawrence, John 13.04.2016 Bulletin 2016/15 Barker Brettell LLP 100 Hagley Road (73) Proprietor: International Flavors & Fragrances Inc. Edgbaston New York, NY 10019 (US) Birmingham B16 8QQ (GB) (72) Inventors: (56) References cited: • CHIN, Hsi-Wen EP-A1- 2 641 479 WO-A1-2013/085014 Tinton Falls, NJ 07724 (US) JP-A- 2006 191 826 JP-A- 2007 176 919 JP-B1- 4 606 505 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Division of Pharmaceutical Biology Faculty of Pharmacy University of Helsinki
    Division of Pharmaceutical Biology Faculty of Pharmacy University of Helsinki Plant secondary metabolites in Peucedanum palustre and Angelica archangelica and their plant cell cultures Manu Juho Mikael Eeva ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Pharmacy of the University of Helsinki, for public criticism in Auditorium LS.2 (A109) (Latokartanonkaari 7 – Building B) on May 21th, 2010, at 12 o´clock noon. HELSINKI 2010 Supervisors Prof. Heikki Vuorela Ph. D. (Pharm.) Division of Pharmaceutical Biology Faculty of Pharmacy, University of Helsinki, Finland Prof. Pia Vuorela Ph. D. (Pharm.) Pharmaceutical Sciences Åbo Akademi University, Turku, Finland Prof. Raimo Hiltunen Ph. D. (Pharm.) Division of Pharmaceutical Biology Faculty of Pharmacy, University of Helsinki, Finland Reviewers Prof. Riitta Julkunen-Tiitto Ph. D. Department of Biology University of Eastern Finland, Finland Prof. Juha-Pekka Salminen Ph. D. Department of Chemistry University of Turku, Finland Opponent Prof. Elín Soffía Ólafsdóttir Ph. D. (Pharm.) Faculty of Pharmacetical Sciences School of Health Sciences University of Iceland, Iceland ISBN: 978-952-10-6186-8 (paperback) ISSN 1795-7079 ISBN 978-952-10-6187-5 (PDF) http://ethesis.helsinki.fi/ Yliopistopaino, Helsinki 2010 CONTENTS 1 ACKNOWLEDGEMENTS 5 2 ABSTRACT 7 3 LIST OF ORIGINAL PUBLICATIONS 8 4 ABBREVIATIONS 9 5 INTRODUCTION 10 6 REVIEW OF THE LITERATURE 12 6.1 Botany and distribution of A. archangelica and P. palustre 12 6.2 Ethnobotany of A. archangelica and P. palustre 14 6.3
    [Show full text]
  • Assessment Report on Levisticum Officinale Koch, Radix Based on Article 16D(1), Article 16F and Article 16H of Directive 2001/83/EC As Amended (Traditional Use)
    27 March 2012 EMA/HMPC/524623/2011 Committee on Herbal Medicinal Products (HMPC) Assessment report on Levisticum officinale Koch, radix Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Draft Herbal substance(s) (binomial scientific name of Levisticum officinale Koch, radix the plant, including plant part) Lovage root Herbal preparation(s) Comminuted herbal substance Pharmaceutical forms Comminuted herbal substance as herbal tea for oral use Rapporteur Assessor(s) Note: This Assessment Report is published to support the release for public consultation of the draft Community herbal monograph on Levisticum officinale Koch, radix. It should be noted that this document is a working document, not yet fully edited, and which shall be further developed after the release for consultation of the monograph. Interested parties are welcome to submit comments to the HMPC secretariat, which the Rapporteur and the MLWP will take into consideration but no ‘overview of comments received during the public consultation’ will be prepared in relation to the comments that will be received on this assessment report. The publication of this draft assessment report has been agreed to facilitate the understanding by Interested Parties of the assessment that has been carried out so far and led to the preparation of the draft monograph. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • Approche Métabolomique Pour Une Caractérisation Plus Fine D'extraits De Plantes D'intérêts Pour La Santé Humaine
    Approche métabolomique pour une caractérisation plus fine d’extraits de plantes d’intérêts pour la santé humaine Julien Delecolle To cite this version: Julien Delecolle. Approche métabolomique pour une caractérisation plus fine d’extraits de plantes d’intérêts pour la santé humaine. Biologie végétale. Université de Strasbourg, 2017. Français. NNT : 2017STRAJ012. tel-01559676 HAL Id: tel-01559676 https://tel.archives-ouvertes.fr/tel-01559676 Submitted on 10 Jul 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Thèse de doctorat de l’Université de Strasbourg Ecole doctorale des Sciences de la Vie et de la Santé (ED 414) Discipline : Sciences de la vie, biologie, biochimie UPR 2357 Institut de Biologie Moléculaire des Plantes Approche métabolomique pour une caractérisation plus fine dextraits de plantes dintérêts pour la santé humaine Présentée par Julien DELECOLLE Pour obtenir le grade de Docteur de l’Université de Strasbourg Soutenance le 03 mars 2017 Membres de la commission dexamen Pr. Raphaël DUVAL Rapporteur externe Pr. Alain HEHN Rapporteur externe Dr. Christine SCHAEFFER-REISS Examinateur interne Dr. Dimitri HEINTZ Directeur de thèse Table des matières INTRODUCTION 1 I. Contexte de la thèse 1 II.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases Chemicals Found in Angelica Archangelica
    Dr. Duke's Phytochemical and Ethnobotanical Databases Chemicals found in Angelica archangelica Activities Count Chemical Plant Part Low PPM High PPM StdDev Refernce Citation 0 (+)-ALPHA-COPAENE Seed Essent. Oil -- 0 (+)-ALPHA-CURCUMENE Root Essent. Oil -- 0 (+)-CUPARENE Root -- 0 (+)-LIMONENE Root -- 0 (+)-OXYPEUCEDANIN Root -- 0 1,1-DIETHOXYHEXANE Root -- 0 1,1-DIETHOXYHEXANE Root Essent. Oil -- 0 1,1-DIETHOXYOCTANE Root -- 0 1,1-DIETHOXYOCTANE Root Essent. Oil -- 0 1,8-CINEOL Fruit Essent. Oil 538000.0 1.0 -- 0 1-O-BETA-D- Plant Pakistan Encyclopedia Planta GLUCOPYRANOSYL- Medica. 1986. (2S,3P)-3-HYDROXY- MARMESINE 0 12-METHYL-13- Root 1.0 12.0 -- TRIDECANOLIDE 0 12-METHYL-OMEGA- Root Essent. Oil -- TRIDECANOLIDE 0 12-METHYL-OMEGA- Root -- TRIDECANOLIDE 0 13-TRIDECANOLIDE Root 15.0 50.0 -- 0 15- Root Wealth of India. HYDROXYPENTADECANOI C-ACID 0 15-PENTADECANOLIDE Root 15.0 75.0 -- 0 17-HEPTADECANOLIDE Root 2.0 20.0 -- 1 2'-ANGELOYL-3'- Root Phytochem. Anal. 3(1):42-48. ISOVALERYL-VAGINATE 1992 0 2'-BETA-D- Plant Pakistan Encyclopedia Planta GLUCOPYRANOSYLOXY- Medica. 1986. MARMESINE 0 2-DECANONE Root Lawrence, B.M., Essential Oils 1976-1977, Essential Oils 1978, Essential Oils 1979-1980. 0 2-NITRO-1,5-P- Plant J.S. Glasby Dict.Pls MENTHADIENE Containing 2ndary Metabolite. 1991. Activities Count Chemical Plant Part Low PPM High PPM StdDev Refernce Citation 2 2-NONANONE Root 1.0 -- 0 2-PENTYL-FURAN Root 0.0 4.0 1.0 -- 0 4,4,6- Root -- TRIMETHYLCYCLOHEX-2- EN-1-ONE 0 4-ETHOXY-1-P-MENTHENE Root 3.0 -- 0 4-METHOXY-7- Seed Leung, A.
    [Show full text]
  • Assessment Report on Levisticum Officinale Koch, Radix
    20 November 2012 EMA/HMPC/524623/2011 Committee on Herbal Medicinal Products (HMPC) Assessment report on Levisticum officinale Koch, radix Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Final Herbal substance(s) (binomial scientific name of Levisticum officinale Koch, radix the plant, including plant part) Herbal preparation(s) Comminuted herbal substance Pharmaceutical forms Comminuted herbal substance as herbal tea for oral use Rapporteur Ewa Widy Tyszkiewicz Assessor(s) Ewa Widy Tyszkiewicz 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 3 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 3 1.2. Information about products on the market in the Member States ............................... 5 1.3. Search and assessment methodology ..................................................................... 6 2. Historical data on medicinal use .......................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0052718A1 Rangel (43) Pub
    US 2011 0052718A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0052718A1 Rangel (43) Pub. Date: Mar. 3, 2011 (54) SYNERGISTIC PHYTOCEUTICAL A6IR 36/4I (2006.01) COMPOSITIONS A636/7 (2006.01) A636/74 (2006.01) (76) Inventor: José Angel Olalde Rangel, Caracas A636/734 (2006.01) (VE) A6IR 36/45 (2006.01) A6II 35/32 (2006.01) (21) Appl. No.: 12/942,766 A6IP 9/00 (2006.01) A6IP5/00 (2006.01) (22) Filed: Nov. 9, 2010 A6IP 700 (2006.01) Related U.S. Application Data (52) U.S. Cl. .................................... 424/549; 424/195.15 (60) Division of application No. 1 1/271,940, filed on Nov. (57) ABSTRACT 10, 2005, now Pat. No. 7,303,772, Continuation of Phytoceutical compositions for the prevention and treatment application No. 12/705,525, filed on Feb. 12, 2010. of circulatory disorders, feminine endocrine disorders, and O O dermal disorders. A specific combination of extracts of plants Publication Classification is taught, as well as principles for varying the formulations (51) Int. Cl. based on categorizing plants into one of three groups, Energy, A6 IK 36/074 (2006.01) Bio-Intelligence, and Organization and selecting several A6 IK 36/258 (2006.01) plants from each group. Such combinations have synergistic A6 IK 36/28 (2006.01) effects, with minimal side effects. riographic eficience afiabetic rati remissists, irreiraig fest of treatast aetgees hairs. appier trasound se Patent Application Publication Mar. 3, 2011 Sheet 1 of 3 US 2011/0052718A1 fisiae : yesigraisie eitiece 3 filiateig cit reasissists, it airig eigth of treatifier eater ghatas.
    [Show full text]
  • Reflection Paper on Risk Associated with the Use of Herbals Containing
    European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 31 October 2007 Doc. Ref. EMEA/HMPC/317913/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL REFLECTION PAPER ON THE RISKS ASSOCIATED WITH FUROCOUMARINS CONTAINED IN PREPARATIONS OF ANGELICA ARCHANGELICA L. DRAFT AGREED BY THE HMPC October 2006 ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION 11 January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) 15 May 2007 ADOPTION BY HMPC 31 October 2007 KEYWORDS HMPC, herbal medicinal products, Angelica archangelica L., furocoumarins, phototoxicity 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged DRAFT REFLECTION PAPER ON THE RISKS ASSOCIATED WITH FUROCOUMARINS CONTAINED IN PREPARATION OF ANGELICA ARCHANGELICA L. TABLE OF CONTENTS 1. INTRODUCTION (BACKGROUND) ........................................................................................ 3 2. SAFETY EVALUATION OF FUROCOUMARINS (CAS NUMBER 66-97-7) ..................... 3 2.1 PHOTOTOXICITY OF FUROCOUMARINS .................................................................................... 3 2.2 CARCINOGENIC POTENTIAL OF FUROCOUMARINS ................................................................... 4 2.3 MECHANISM OF ACTION .........................................................................................................
    [Show full text]
  • Botanical Name Family Synonym Part Traditionally Used/Specific
    Botanical name Family Synonym Part Part of chemical Info Comments Notes References traditionally concern used/specific preparations Abies alba Mill. Pinaceae bark, branch, Branches: essential Toxicity due to beta-phellandrene beta-phellandrene Yang, S. A., Jeon, S. K., needle, oil (0.2%-0.5%): should be stated. Pure EO should not content should not Lee, E. J., Im, N. K., Jhee, seed, resin bornyl acetate be consumed directly (<0.02 ml of exceed 100 ppm K. H., Lee, S. P., & Lee, I. (30.31%), EO). Content should be stated. (0.01%) daily. S. (2009). Radical camphene scavenging activity of (19.81%), 3-carene the essential oil of silver (13.85%), fir (Abies alba). Journal tricyclene of clinical biochemistry (12.90%), dl- and nutrition, 44(3), 253.; limonene (7.50%), Luebke, W. (2011). beta- α-pinene (2.87%), phellandrene 555-10-2. caryophyllene (2.18%), β- phellandrene (2.13%), borneol (1.74%), bicyclo[2.2.1]hept- 2-ene,2,3-dimethyl (1.64%) and α- terpinene (1.24%) Abies balsamea Pinaceae bark, needle, Essential oil needle Toxicity due to beta-pinene should beta-pinene Pichette, A., Larouche, (L.) Mill. resin, twig; twig (0.6%-1.4%): be stated. Pure EO should not be content should not P. L., Lebrun, M., & essential oil e.g. beta pinene consumed directly (<0.03 ml of EO). exceed 100 ppm Legault, J. (2006). (24%-35%), alpha Content should be stated. (0.01%) daily. Composition and pinene ((6%-11%), antibacterial activity of camphen ((6%- Abies balsamea 11%), . Resin: essential oil. contains 16%-27% Phytotherapy Research, essential oil.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases Chemicals Found in Angelica Archangelica
    Dr. Duke's Phytochemical and Ethnobotanical Databases Chemicals found in Angelica archangelica Activities Count Chemical Plant Part Low PPM High PPM StdDev Refernce Citation 0 (+)-ALPHA-COPAENE Seed Essent. Oil -- 0 (+)-ALPHA-CURCUMENE Root Essent. Oil -- 0 (+)-CUPARENE Root -- 0 (+)-LIMONENE Root -- 0 (+)-OXYPEUCEDANIN Root -- 0 1,1-DIETHOXYHEXANE Root -- 0 1,1-DIETHOXYHEXANE Root Essent. Oil -- 0 1,1-DIETHOXYOCTANE Root Essent. Oil -- 0 1,1-DIETHOXYOCTANE Root -- 0 1,8-CINEOL Fruit Essent. Oil 538000.0 1.0 -- 0 1-O-BETA-D- Plant Pakistan Encyclopedia Planta GLUCOPYRANOSYL- Medica. 1986. (2S,3P)-3-HYDROXY- MARMESINE 0 12-METHYL-13- Root 1.0 12.0 -- TRIDECANOLIDE 0 12-METHYL-OMEGA- Root Essent. Oil -- TRIDECANOLIDE 0 12-METHYL-OMEGA- Root -- TRIDECANOLIDE 0 13-TRIDECANOLIDE Root 15.0 50.0 -- 0 15- Root Wealth of India. HYDROXYPENTADECANOI C-ACID 0 15-PENTADECANOLIDE Root 15.0 75.0 -- 0 17-HEPTADECANOLIDE Root 2.0 20.0 -- 1 2'-ANGELOYL-3'- Root Phytochem. Anal. 3(1):42-48. ISOVALERYL-VAGINATE 1992 0 2'-BETA-D- Plant Pakistan Encyclopedia Planta GLUCOPYRANOSYLOXY- Medica. 1986. MARMESINE 0 2-DECANONE Root Lawrence, B.M., Essential Oils 1976-1977, Essential Oils 1978, Essential Oils 1979-1980. 0 2-NITRO-1,5-P- Plant J.S. Glasby Dict.Pls MENTHADIENE Containing 2ndary Metabolite. 1991. Activities Count Chemical Plant Part Low PPM High PPM StdDev Refernce Citation 2 2-NONANONE Root 1.0 -- 0 2-PENTYL-FURAN Root 0.0 4.0 1.0 -- 0 4,4,6- Root -- TRIMETHYLCYCLOHEX-2- EN-1-ONE 0 4-ETHOXY-1-P-MENTHENE Root 3.0 -- 0 4-METHOXY-7- Seed Leung, A.
    [Show full text]
  • Botanical Name Family Synonym Part Traditionally Used/Specific
    Botanical name Family Synonym Part traditionally Part of chemical Info particular Present in used/specific concern considerations x preparations countries Abelmoschus esculentus (L.) Malvaceae fruit Food (Okra) OK 1 Moench Abelmoschus moschatus Malvaceae seed Essential oil: pyrazine and pyridine derivatives. Young leaves and OK 1 Medik. shoots are eaten Abies alba Mill. Pinaceae bark, branch, Branches: essential oil (0.2%-0.5%): bornyl acetate (30.31%), OK 3 needle, seed, resin camphene (19.81%), 3-carene (13.85%), tricyclene (12.90%), dl- limonene (7.50%), α-pinene (2.87%), caryophyllene (2.18%), β- phellandrene (2.13%), borneol (1.74%), bicyclo[2.2.1]hept-2-ene,2,3- dimethyl (1.64%) and α-terpinene (1.24%) Abies balsamea (L.) Mill. Pinaceae bark, needle, resin, Essential oil needle twig (0.6%-1.4%): e.g. beta pinene (24%-35%), OK 3 twig; essential oil alpha pinene ((6%-11%), camphen ((6%-11%), . Resin: contains 16%- 27% essential oil. Sesquiterpene derivatives: e.g. bisabolene. Resin acids: e.g. canadinol acids Abies nordmanniana subsp. Pinaceae Abies pectinata bark, branch, needle Bark : tannins 10%. Essential oil in needles, branches, bark and resin: OK 1 equi-trojani (Asch. & Sint. ex Dc. Var. Equi- 0.24-0.35%. Sometimes used as falsification for Abies alba Boiss.) Coode & Cullen Trojani Asch. & Sint. Ex Boiss Abies sibirica Ledeb. Pinaceae bark, branch, Needle: essential oil (1.3%-2%): e.g. bornylacetate ( 20%-40%), OK 3 needle, seed, resin camphene (10%-26%), alpha pinene (8%-20%), beta pinene (3%-13%) Botanical name Family Synonym Part traditionally Part of chemical Info particular Present in used/specific concern considerations x preparations countries Abroma augusta L.
    [Show full text]
  • Four Coumarins from Heracleum Yunngningense
    June 2005 Notes Chem. Pharm. Bull. 53(6) 701—704 (2005) 701 Four Coumarins from Heracleum yunngningense a a a b ,a Masahiko TANIGUCHI, Osamu YOKOTA, Makio SHIBANO, Nian-He WANG, and Kimiye BABA* a Osaka University of Pharmaceutical Sciences; 4–20–1 Nasahara, Takatsuki, Osaka 569–1094, Japan: and b Institute of Botany, Jiangsu Province and Academia Sinica; 210014, Nanjing, China. Received January 13, 2005; accepted March 1, 2005 Four new coumarins (1—4) were isolated from the roots of Heracleum yunngningense HAND.–MASS. Their structures were established by spectral analyses. Key words Heracleum yunngningense; Umbelliferae; coumarin The roots of Heracleum yunngningense HAND.–MASS., “永 Compound 1, colorless needles, mp 158—160 °C, was as- ϩ 寧独活”, is a Chinese folk medicine used as an antipyretic, signed the molecular formula C12H10O6 ([M] m/z 250.0465) analgesic, and diaphoretic agent in local areas of Yunnan by high resolution electron impact (HR-EI)-MS. The UV province, China.1,2) In the course of our studies of the chemi- spectrum showed absorption maxima at 293.7, 216.2 and cal constituents of Umbelliferous plants, we have isolated 206.6 nm and IR spectrum absorption bands at 2963, 1731, four new coumarins, yunngnin A (1), yunngnin B (2), yunng- 1648, 1594, 1475 and 1424 cmϪ1, suggesting the presence of noside A (3), and yunngnoside B (4), in addition to a poly- an aromatic ring, an unsaturated lactone and hydroxyl acetylen, falcarindiol, two phenylpropanoids, ferulic acid, p- groups. The 1H- and 13C-NMR spectra (Table 1) of 1 showed
    [Show full text]